Thu.Jan 04, 2024

article thumbnail

Paxlovid Found Not to Reduce Long COVID Risk

Drug Topics

A new study found that 16.1% of patients treated with nirmatrelvir-ritonavir (Paxlovid) reported long COVID symptoms, compared to 14% of untreated patients.

241
241
article thumbnail

Statins Could Potentially Slow Deterioration of Cognitive Function for Those With Alzheimer Disease

Pharmacy Times

Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.

177
177
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Hospitals Reinstate Mask Guidelines Against Triple Threat of Respiratory Illnesses

Drug Topics

In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.

Hospitals 201
article thumbnail

Poor Sleep Quality in Early Adulthood Linked With Worse Cognitive Performance in Middle Age

Pharmacy Times

The risk of poor cognitive performance was nearly double in participants who had the greatest number of sleep disturbances compared to the least.

177
177
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Moderate Carbohydrate Diet May Improve Glucose Control in Patients With T1D

Drug Topics

Patients on a moderate carbohydrate diet increased their time in range by 4.7% and decreased their time above range by 5.9%.

197
197
article thumbnail

COVID-19 May Be Linked to a Long-Term Decrease in Cognitive Abilities in Hospitalized Patients

Pharmacy Times

However, cognitive performance was not significantly worse than patients hospitalized for other conditions of a similar severity.

Hospitals 153

More Trending

article thumbnail

Ashwagandha: A Case Example of the Supplement Industry

Pharmacy Times

Perhaps ashwagandha may aid in stress management, athletic performance, and sleep, but this effect is far from definitive.

145
145
article thumbnail

Baby monitor videos yield evidence for long-suspected link between seizures and unexplained toddler deaths

STAT

The baby monitor didn’t go off. Any sound or motion in the twins’ room was supposed to set off an alarm — but in the wee hours of Nov. 27, 2022, Katie Czajkowski-Fell and Justin Fell weren’t woken up. They’d gotten it because of Hayden’s febrile seizures. These are common, generally nothing to worry about, the doctors said.

article thumbnail

Gepirone Offers New Option for Major Depressive Disorder

Pharmacy Times

Gepirone does not induce sexual dysfunction, a common limitation associated with SSRIs.

138
138
article thumbnail

Novo Nordisk, Eli Lilly's weight-loss drugs under FDA scrutiny for suicidal thoughts, hair loss

Fierce Pharma

Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?

FDA 137
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi

STAT

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June. Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference , while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs.

136
136
article thumbnail

Why amplifying the patient voice is crucial to clinical trial success

pharmaphorum

Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.

131
131
article thumbnail

After loved ones’ long-awaited organ transplants, caregivers often find challenges are just beginning

STAT

By the time his wife Glenda Daggert received a double organ transplant in 1999, Ira Copperman already had a lot of experience as a caregiver. The couple had been together for over two decades, married for one, and Copperman had become accustomed to helping Daggert manage her diabetes and its complications. Mixing insulin, going along for doctor’s visits, administering injections: it was all routine.

135
135
article thumbnail

WBA posts Q1 results

Drug Store News

WBA’s first quarter sales increased 10% from the year-ago quarter to $36.7 billion, an increase of 8.7% on a constant currency basis.

122
122
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

STAT

Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for a type of blood cancer — a concession that competition from personalized CAR-T treatments, already entrenched in the market, has become more challenging. In a strategic pivot, two clinical trials involving patients with later-stage lymphoma are being shut down.

135
135
article thumbnail

Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal

Fierce Pharma

Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio keeps striding forward with its sickle cell disease gene therapy Lyfgenia. | Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio has signed a second outcomes-based reimbursement agreement for its sickle cell gene therapy Lyfgenia.

122
122
article thumbnail

STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff

STAT

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.  The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds.

133
133
article thumbnail

2024 forecast: As CDMOs come off pandemic's highs and lows, employment and funding hitches persist

Fierce Pharma

Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields. | Even after the heady highs of the COVID era, the CDMO realm remains one of biopharma's buzziest fields. In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry.

119
119
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: An injectable gel enters the male birth control fray with early positive clinical data

STAT

Between condoms and vasectomies lies a vast, undeveloped chasm of male birth control. Contraline, a device startup that released early, positive clinical data in a press release on Thursday, hopes to fill it. The company has built an injectable gel that’s inserted into the sperm duct, physically blocking the sperm from coming out. Investigators tested the device on 23 participants in Australia last year and recorded no serious adverse events.

132
132
article thumbnail

Costs of treating COVID-19 hospitalizations quintupled medical inflation across the pandemic

Fierce Healthcare

The cost of treating a COVID-19 hospital patient in the hospital rose by 26% over the first two years of the pandemic, more than five times the rate of medical inflation during that time, according | On average and after adjustments, direct treatment costs for a COVID-19 hospital admission rose 26%, from $10,394 in March 2020 to $13,072 in March 2022, researchers found in a new analysis of 1.3 million inpatient stays.

Hospitals 118
article thumbnail

STAT+: Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk

STAT

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand. Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures.

131
131
article thumbnail

Biologics Treatment Response Patterns Comparable in Patients With ACO, Asthma

Pharmacy Times

The efficacy of biologics suggests a potential for biologic-based treatment for patients with asthma-chronic obstructive pulmonary disease overlap.

117
117
article thumbnail

STAT+: Burning questions for the 2024 JPM Healthcare Conference

STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods. This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot.

130
130
article thumbnail

AGC extends CDMO expansion spree, plans second manufacturing facility in Japan

Fierce Pharma

Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. | Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

115
115
article thumbnail

STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

STAT

Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday. Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity.

article thumbnail

CVS Caremark to kick AbbVie's Humira off some formularies in favor of cheaper biosimilars

Fierce Pharma

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. | The changes to major commercial formularies will take effect April 1 and favor Humira biosimilar options over the branded drug as part of CVS' efforts to ramp up U.S. biosimilar adoption.

115
115
article thumbnail

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

STAT

Several advocacy groups are blasting a Food and Drug Administration proposal to work with a Denver Health surveillance system for monitoring misuse of prescription opioids over long-standing ties the operation has to the pharmaceutical industry. At issue is the Research, Abuse, Diversion, and Addiction-Related Surveillance system, or RADARS, which was originally created as in-house monitoring program by Purdue Pharma and later sold to the Denver Health and Hospital Authority.

FDA 125
article thumbnail

Ulta Beauty revamps loyalty program

Drug Store News

Ulta Beauty’s Ultamate Rewards loyalty program will now be known as Ulta Beauty Rewards.

111
111
article thumbnail

STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more

STAT

Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will draw on a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us.

FDA 120
article thumbnail

Roche antibiotic tackles serious drug-resistant pathogen

pharmaphorum

Scientists at Roche and Harvard University have discovered a new class of antibiotic that can kill carbapenem-resistant Acinetobacter baumannii (CRAB), a major public health threat

111
111
article thumbnail

STAT+: Health tech’s 2024 hiring outlook: Balance tips toward employers

STAT

Health tech hopefuls might once have been used to a wealth of job options, especially in the pandemic’s early stages when investors pumped record-breaking dollar amounts into an unprecedented number of ventures. That glut of opportunities meant workers could bargain harder for better job offers, demanding perks and flexibilities like permanent remote work or expensive fertility benefits.

117
117
article thumbnail

Click bags FDA breakthrough tag for schizophrenia DTx

pharmaphorum

Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia, like social withdrawal and apathy, that tend not to respond well to antipsychotic drugs.

FDA 111
article thumbnail

Regulatory revision essential for bioprocess IIoT adoption

European Pharmaceutical Review

According to a paper recently published in the Biochemical Engineering Journal , challenges such as strict regulation and lack of industry awareness, limit the adoption of Industrial Internet of Things (IIoT) in bioprocessing and overall bioproduction. As a system that uses various technologies , such as data analytics and artificial intelligence (AI), to transfer data between each other autonomously in an industrial setting, IIoT “enables wide-scope data collection and utilisation, and reduces

111
111